Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study in healthy volunteers to determine whether different drugs metabolised by the liver have any effects on how NRL972 is processed within the body.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Reference | Experimental | No pre-treatment |
|
| T1 | Experimental | Cloxacillin pre- and co-treatment |
|
| T2 | Experimental | UDCA pre-treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NRL972 | Drug | Single intravenous administration of 2 mg NRL972 |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Total clearance by non-compartmental analysis. Apparent terminal disposition half-life t½ by non-compartmental analysis | 4 hours post-dose |
| Measure | Description | Time Frame |
|---|---|---|
| Non-compartmental PK-analysis based on the extensive profile (up to last quantifiable data point), the 'short' profile (over the first hour after injection), and the two-point profile based on selected data-pairs over the 1st hour after dosing | 4 hours post-dose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
General - all subjects
Previous participation in the trial
Participant in any other trial during the last 90 days
Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months
History of any clinically relevant allergy (including hypersensitivity to the trial medications)
Presence of acute or chronic infection
Presence or history of any relevant co-morbidity
Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg
Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular
Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes
Positive serology for HBsAg, anti HBc and anti HCV
Positive HIV test
Positive alcohol or urine drug test on recruitment (and upon admission)
History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol
Smoking more than 15 cigarettes/day or equivalent of other tobacco products
Use of prohibited medication
Suspicion or evidence that the subject is not trustworthy and reliable
Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard
General - all females
Positive pregnancy test
Lactating
Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermicidal gel] should be us
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hans-Jürgen Gruss, MD | Norgine | Study Director |
| Emil Gatchev, PD Dr med | MHAPT "Zarita Johanna" University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MHAPT "Zarita Johanna" University Hospital | Sofia | 1431 | Bulgaria |
Not provided
| ID | Term |
|---|---|
| D008103 | Liver Cirrhosis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| C000601594 | NRL972 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| NRL972 |
| Drug |
Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972. |
|
| NRL972 | Drug | Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1 |
|
| D013568 |
| Pathological Conditions, Signs and Symptoms |